BioNTech SE (NASDAQ:BNTX) Q2 2025 Earnings Call Transcript
Douglas Maffei: Thank you, operator. Good morning and good afternoon. Thank you for joining BioNTech's Second Quarter 2025 Earnings Call.
Biontech Se (BNTX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 368,923 | $39,279,232 | +720% | 0.38% |
| 2. | Squarepoint Ops LLC Maxime Fortin (Cio) | 335,660 | $35,737,720 | -4% | 0.04% |
| 3. | Tang Capital Management Kevin C. Tang | 270,000 | $28,746,900 | 1.45% | |
| 4. | Long Focus Capital Management John B. Helmers | 207,903 | $22,135,432 | +31% | 0.84% |
| 5. | 170,800 | $18,185,076 | -25% | 0% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,159,011 | $868,689,846 | 0.05% | |
| 2. | 8,038,872 | $855,898,702 | 0.64% | |
| 3. | 4,230,098 | $450,378,534 | 1.84% | |
| 4. | 4,001,466 | $426,036,087 | 0.34% | |
| 5. | 3,658,361 | $389,505,696 | 67.6% |
News See All
Recent Agreements Set To Bolster BioNTech SE (BNTX)'s Oncology Arm
On June 2, the company announced that it had agreed with Bristol Myers Squibb for the global joint development and commercialization of BioNTech SE (NASDAQ:BNTX)’s investigational bispecific antibody...
13 Best German Stocks to Invest in Now
However, on a year-to-date basis, the DAX index has gained 19.48%, comfortably outperforming its US counterparts, driven by a robust show by the country’s defense stocks, as European governments unlocked...
Truist Lifts BioNTech (BNTX) Price Target After New Partnership
This decision came after the company entered into an agreement with Bristol Myers Squibb for the co-development and co-commercialization of BioNTech SE’s (NASDAQ:BNTX) investigational bispecific antibody...
Why BioNTech SE (BNTX) Skyrocketed On Monday
We recently published a list of These 10 Stocks Blew Past Expectations.
Bristol-Myers Squibb Company and BioNTech SE Partner to Advance Next-Gen Cancer Therapies
Bristol-Myers Squibb Company (NYSE:BMY), which focuses on innovative cancer and immunology treatments, is a leader in the global biopharmaceutical market.
Bristol-Myers (BMY) Licenses BioNTech's Immunotherapy in $11 billion Deal
On Monday, June 2, Bloomberg reported that Bristol-Myers Squibb Company (NYSE:BMY) and BioNTech SE (NASDAQ:BNTX) announced a strategic licensing agreement focused on next-generation oncology therapies...
BioNTech Strengthens UK Ties with Investment of Up to $1.33 Billion
German vaccine maker BioNTech SE (NASDAQ:BNTX) revealed on May 20 that it intends to boost its presence in the UK with an investment of up to £1 billion ($1.33 billion) over the next decade, focusing...
12 Best Growth Stocks to Buy and Hold for the Long Term
The market closed last week mostly lower, however, the S&P 500 has been up more than 7% since April 11, indicating a returning positive sentiment.
BioNTech SE (NASDAQ:BNTX) Q1 2025 Earnings Call Transcript
Michael Horowicz: Thank you. Good morning, and good afternoon. Thank you for joining BioNTech's first quarter 2025 earnings call.
Billionaire Hedge Funds
